Aging Populations And China Expansion Will Drive Device Adoption

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 Mar 25

Updated

12 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

21.8%

7D

-1.0%

Loading

1Y

21.8%

7D

-1.0%

You can edit this narrative until Dec 13 12:10 PM. Then, changes will post as Updates.

Author's Valuation

US$69.19.2% undervalued

AnalystConsensusTarget Fair Value

Shared on 12 Dec 25

LIVN: Improved Reimbursement And Raised Guidance Will Support Measured 2025 Outlook

Analysts have modestly revised their price target for LivaNova to remain effectively unchanged at approximately 69 dollars per share. This reflects stable assumptions around revenue growth, profitability, and valuation multiples, despite only incremental tweaks to the discount rate and long term earnings expectations.

Shared on 28 Nov 25

Fair value Increased 0.14%

LIVN: Reimbursement Rate Increases And Guidance Raise Will Support 2025 Momentum

Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.

Shared on 14 Nov 25

Fair value Increased 6.15%

LIVN: Upgraded 2025 Outlook Will Drive Confidence Amid Business Momentum

Narrative Update on LivaNova Analyst Price Target Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.

Shared on 08 Aug 25

Fair value Increased 0.46%

Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).

Shared on 01 May 25

Fair value Increased 8.38%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 2.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.92%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$69.1

9.2% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

6.68%

Medical Equipment revenue growth rate

8.17%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.48%

Calculation

US$171.40m

Earnings '28

x

28.32x

PE Ratio '28

=

US$4.85b

Market Cap '28

US$4.85b

Market Cap '28

/

55.37m

No. shares '28

=

US$87.64

Share Price '28

US$87.64 Share Price '28

Discounted to 2025 @ 8.49% p.a.

=

US$68.63

Fair Value '25